#USA #Los Angeles #Securities Fraud #Ardelyx #SBS Law

A Call to Action for Ardelyx, Inc. Investors

In a recent development for shareholders, Schall, Brown & Schwartz LLP (SBS), a prominent national firm specializing in shareholder rights litigation, is reminding those who invested in Ardelyx, Inc. (NASDAQ: ARDX) about a significant class action lawsuit over securities fraud claims. This legal action raises alarms regarding suspected violations of the Securities Exchange Act of 1934 by the company, specifically under sections §§10(b) and 20(a) along with Rule 10b-5, which is enforced by the U.S. Securities and Exchange Commission.

The lawsuit centers around the period from January 13, 2025, to August 6, 2026, during which shareholders may have been misled about the company's performance. SBS is urging investors that acquired ARDX shares during this timeframe to come forward, particularly as the deadline to join the case approaches on November 16, 2026. It's crucial to note that becoming a lead plaintiff is not a prerequisite for claiming recovery in this lawsuit.

Background on the Claims

According to the filed complaint, Ardelyx is accused of making misleading statements regarding its business operations. These declarations contributed to an inflated perception of the company’s efficiency and market conditions while concealing significant transparency issues. Key among the complaints are the reimbursement barriers that arose, which severely limited patient access to Ardelyx's drugs, particularly the products XPHOZAH and IBSRELA. Furthermore, the lawsuit highlights that patient initiation of new treatments and prescription fulfillment faced considerable delays due to increasingly strict prior authorization and step-edit requirements.

The Consequences of Misleading Statements

These obstacles to patient access have not only impeded the commercial viability of the company's primary offerings but have also allegedly led to false representations made to the market. As the reality of Ardelyx's operational challenges unfolded, it became clear that the company's earlier public statements were materially misleading. The resulting fallout was a loss for investors when the facade of Ardelyx's supposed success was shattered, leading to a decline in stock value.

Who Can Join the Lawsuit?

If you are a shareholder who experienced losses due to the downturn in Ardelyx’s stock price within the mentioned time frame, it is imperative to consider participating in this class action suit. Engaging with SBS can help clarify your rights and the potential for recovering lost investments. Contacting Brian Schall or David Schwartz from SBS is highly encouraged, as they provide free consultations to discuss your standing and options in regards to this case.

Next Steps for Investors

Potential lead plaintiffs or interested shareholders should act promptly. In order to secure your place in the lawsuit, contact SBS at their Los Angeles office or through their website: www.schallfirm.com. Time is of the essence, and understanding your position is crucial as the November deadline nears. It should be emphasized that if you choose not to engage in this lawsuit, you may remain an absent class member without representation.

Why Choose SBS?

SBS has established a reputation for fighting for the rights of investors globally, with a dedicated focus on securities class action lawsuits. The expertise brought in by the founding partners is extensive, equipping them to advocate fiercely for every investor’s cause.

In conclusion, the unfolding developments surrounding Ardelyx, Inc. offer a pivotal moment for shareholders affected by the alleged misconduct. Seizing this opportunity to join the class action lawsuit may not only address personal losses but also contribute to the broader accountability of corporate practices within the pharmaceutical sector.